Scalper1 News
Big-cap biotech Celgene made its name as a cancer fighter, but now it’s branching out into diseases of the immune system. And one of the biggest tests of this new strategy comes this weekend. At the United European Gastroenterology Week in Vienna, which runs Saturday to Oct. 22, Celgene (CELG) is set to present phase-two data on GED-0301, a treatment for Crohn’s disease, an inflammatory disease of the GI tract. Celgene licensed the drug in April Scalper1 News
Scalper1 News